Scotiabank Initiates Coverage On Beam Therapeutics with Sector Perform Rating, Announces Price Target of $24

Benzinga · 10/16 14:31
Scotiabank analyst Greg Harrison initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform rating and announces Price Target of $24.